Inflammation and schizophrenia

References

• Muller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. The immune system and schizophrenia. An integrative view. Ann. NY Acad. Sci.917, 456–467 (2000).
   PubMed Web of Science ®Google Scholar
• Maes M, Bocchio Chiavetto L, Bignotti S et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res.54, 281–291 (2002).
   PubMed Web of Science ®Google Scholar
• Sirota P, Meiman M, Herschko R, Bessler H. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-α and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res.134, 151–159 (2005).
   PubMedGoogle Scholar
• Rapaport MH, Lohr JB. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr. Scand.90, 311–315 (1994).
   PubMedGoogle Scholar
• Brown AS, Cohen P, Harkavy-Friedman J et al. A.E. Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol. Psychiatry49, 473–486 (2001).
   PubMed Web of Science ®Google Scholar
• Mednick SA, Machon RA, Huttunen MO, Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch. Gen. Psychiatry45, 189–192 (1988).
   PubMed Web of Science ®Google Scholar
• Brown AS, Schaefer CA, Quesenberry CP Jr, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am. J. Psychiatry162, 767–773 (2005).
   PubMed Web of Science ®Google Scholar
• Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH. Maternal infections and subsequent psychosis among offspring. Arch. Gen. Psychiatry58, 1032–1037 (2001).
   PubMed Web of Science ®Google Scholar
• Brown AS, Schaefer CA, Quesenberry CP Jr, Shen L, Susser ES. No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia? Am. J. Psychiatry163, 2178–2180 (2006).
   PubMedGoogle Scholar
• Borrell J, Vela JM, Arevalo-Martin A, Molina-Holgado E, Guaza C. Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology26, 204–215 (2002).
   PubMed Web of Science ®Google Scholar
• Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol. Psychiatry59, 546–554 (2006).
   PubMed Web of Science ®Google Scholar
• Eagles JM, Gibson I, Bremner MH, Clunie F, Ebmeier KP, Smith NC. Obstetric complications in DSM-III schizophrenics and their siblings. Lancet335, 1139–1141 (1990).
   Google Scholar
• Jones PB, Rantakallio P, Hartikainen AL, Isohanni M, Sipila P. Schizophrenia as a long-term outcome of pregnancy, delivery, and perinatal complications: a 28-year follow-up of the 1966 north Finland general population birth cohort. Am. J. Psychiatry155, 355–364 (1998).
   PubMed Web of Science ®Google Scholar
• Parnas J, Schulsinger F, Teasdale TW, Schulsinger H, Feldman PM, Mednick SA. Perinatal complications and clinical outcome within the schizophrenia spectrum. Br. J. Psychiatry140, 416–420 (1982).
   PubMed Web of Science ®Google Scholar
• Sacker A, Done DJ, Crow TJ, Golding J. Antecedents of schizophrenia and affective illness. Obstetric complications. Br. J. Psychiatry166, 734–741 (1995).
   PubMed Web of Science ®Google Scholar
• Hultman CM, Ohman A, Cnattingius S, Wieselgren IM, Lindstrom LH. Prenatal and neonatal risk factors for schizophrenia. Br. J. Psychiatry170, 128–133 (1997).
   PubMed Web of Science ®Google Scholar
• Zornberg GL, Buka SL, Tsuang MT. Hypoxic-ischemia-related fetal/neonatal complications and risk of schizophrenia and other nonaffective psychoses: a 19-year longitudinal study. Am. J. Psychiatry157, 196–202 (2000).
   PubMed Web of Science ®Google Scholar
• Rosso IM, Cannon TD, Huttunen T, Huttunen MO, Lonnqvist J, Gasperoni TL. Obstetric risk factors for early-onset schizophrenia in a Finnish birth cohort. Am. J. Psychiatry157, 801–807 (2000).
   PubMed Web of Science ®Google Scholar
• Done, DJ, Johnstone EC, Frith CD, Golding J, Shepherd PM, Crow TJ. Complications of pregnancy and delivery in relation to psychosis in adult life: data from the British perinatal mortality survey sample. Br. Med. J.302, 1576–1580 (1991).
   PubMed Web of Science ®Google Scholar
• McCreadie RG, Hall DJ, Berry IJ, Robertson LJ, Ewing JI, Geals MF. The Nithsdale schizophrenia surveys. X: obstetric complications, family history and abnormal movements. Br. J. Psychiatry160, 799–805 (1992).
   PubMedGoogle Scholar
• Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH. Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. Biol. Psychiatry50, 743–749 (2001).
   PubMed Web of Science ®Google Scholar
• Hara H, Friedlander RM, Gagliardini V et al. Inhibition of interleukin 1β converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc. Natl Acad. Sci. USA94, 2007–2012 (1997).
   PubMed Web of Science ®Google Scholar
• Barone FC, Arvin B, White RF et al. Tumor necrosis factor-α. A mediator of focal ischemic brain injury. Stroke28, 1233–1244 (1997).
   PubMed Web of Science ®Google Scholar
• Bruce AJ, Boling W, Kindy MS et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med.2, 788–794 (1996).
   PubMed Web of Science ®Google Scholar
• Hopkins SJ, Rothwell NJ. Cytokines and the nervous system. I: Expression and recognition. Trends Neurosci.18, 83–88 (1995).
   PubMed Web of Science ®Google Scholar
• Vitkovic L, Bockaert J, Jacque C. “Inflammatory” cytokines: neuromodulators in normal brain? J. Neurochem.74, 457–471 (2000).
   PubMed Web of Science ®Google Scholar
• Mehler MF, Kessler JA. Hematolymphopoietic and inflammatory cytokines in neural development. Trends Neurosci.20, 357–365 (1997).
   PubMed Web of Science ®Google Scholar
• Gilmore JH, Jarskog LF. Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. Schizophr. Res.24, 365–367 (1997).
   PubMed Web of Science ®Google Scholar
• Brown AS, Hooton J, Schaefer CA et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry161, 889–895 (2004).
   PubMed Web of Science ®Google Scholar
• Sastry PS, Rao KS. Apoptosis and the nervous system. J. Neurochem.74, 1–20 (2000).
   PubMed Web of Science ®Google Scholar
• Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science267, 1456–1462 (1995).
   PubMed Web of Science ®Google Scholar
• Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr. Res.81, 47–63 (2006).
   PubMed Web of Science ®Google Scholar
• Benes FM, Walsh J, Bhattacharyya S, Sheth A, Berretta S. DNA fragmentation decreased in schizophrenia but not bipolar disorder. Arch. Gen. Psychiatry60, 359–364 (2003).
   PubMedGoogle Scholar
• Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr. Bull.32, 200–202 (2006).
   PubMed Web of Science ®Google Scholar
• Goff DC. Pharmacologic implications of neurobiological models of schizophrenia. Harv. Rev. Psychiatry13, 352–359 (2005).
   PubMed Web of Science ®Google Scholar
• Gilmore JH, Jarskog LF, Vadlamudi S. Maternal infection regulates BDNF and NGF expression in fetal and neonatal brain and maternal–fetal unit of the rat. J. Neuroimmunol.138, 49–55 (2003).
   PubMed Web of Science ®Google Scholar
• Maes M, Bocchio Chiavetto L, Bignotti S et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur. Neuropsychopharmacol.10, 119–124 (2000).
   PubMed Web of Science ®Google Scholar
• Lin, A, Kenis G, Bignotti S et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res.32, 9–15 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang, XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry65, 940–947 (2004).
   PubMed Web of Science ®Google Scholar
• Larsen GL, Henson PM. Mediators of inflammation. Annu. Rev. Immunol.1, 335–359 (1983).
   PubMed Web of Science ®Google Scholar
• Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? Schizophr. Res.26, 227–233 (1997).
   PubMed Web of Science ®Google Scholar
• Schattner A, Cori Y, Hahn T, Sirota P. No evidence for autoimmunity in schizophrenia. J. Autoimmun.9, 661–666 (1996).
   PubMed Web of Science ®Google Scholar
• Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiatry150, 1408–1410 (1993).
   PubMed Web of Science ®Google Scholar
• el-Mallakh RS, Suddath RL, Wyatt RJ. Interleukin-1α and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog. Neuropsychopharmacol. Biol. Psychiatry17, 383–391 (1993).
   PubMed Web of Science ®Google Scholar
• Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr. Res.25, 123–129 (1997).
   PubMed Web of Science ®Google Scholar
• McAllister CG, van Kammen DP, Rehn TJ et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry152, 1291–1297 (1995).
   PubMed Web of Science ®Google Scholar
• Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin. Chem.46, 461–468 (2000).
   PubMed Web of Science ®Google Scholar
• Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med.164, 1010–1014 (2004).
   PubMedGoogle Scholar
• Lesperance F, Frasure-Smith N, Theroux P, Irwin M. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am. J. Psychiatry.161, 271–277 (2004).
   PubMed Web of Science ®Google Scholar
• Yaffe K, Lindquist K, Penninx BW et al. Inflammatory markers and cognition in well-functioning African–American and white elders. Neurology61, 76–80 (2003).
   Google Scholar
• Weuve J, Ridker PM, Cook NR, Buring JE, Grodstein F. High-sensitivity C-reactive protein and cognitive function in older women. Epidemiology17, 183–189 (2006).
   PubMed Web of Science ®Google Scholar
• Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res.149, 267–271 (2007).
   PubMed Web of Science ®Google Scholar
• Dziedzic T. Systemic inflammatory markers and risk of dementia. Am. J. Alzheimers Dis. Other Demen.21, 258–262 (2006).
   PubMedGoogle Scholar
• Grunze HC, Rainnie DG, Hasselmo ME et al. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci.16, 2034–2043 (1996).
   PubMedGoogle Scholar
• Green MF, Nuechterlein KH, Gold JM et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry56, 301–307 (2004).
   PubMed Web of Science ®Google Scholar
• Bachneff SA. Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. Schizophr. Bull.22, 163–182 (1996).
   PubMedGoogle Scholar
• Shinba T, Nagano M, Kariya N et al. Near-infrared spectroscopy analysis of frontal lobe dysfunction in schizophrenia. Biol. Psychiatry55, 154–164 (2004).
   PubMed Web of Science ®Google Scholar
• Lahti AC, Holcomb HH, Medoff DR, Weiler MA, Tamminga CA, Carpenter WT Jr. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am. J. Psychiatry158, 1797–1808 (2001).
   PubMed Web of Science ®Google Scholar
• Vaiva G, Cottencin O, Llorca PM et al. Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. Prog. Neuropsychopharmacol. Biol. Psychiatry26, 481–485 (2002).
   PubMed Web of Science ®Google Scholar
• Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med. Genet.6, 7 (2005).
   PubMed Web of Science ®Google Scholar
• Biessels GJ, Kamal A, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res.800, 125–135 (1998).
   PubMed Web of Science ®Google Scholar
• Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis. Assoc. Disord.20, 298–301 (2006).
   PubMed Web of Science ®Google Scholar
• Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology74, 270–280 (2001).
   PubMed Web of Science ®Google Scholar
• Park CR, Seeley RJ, Craft S, Woods SC. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol. Behav.68, 509–514 (2000).
   PubMed Web of Science ®Google Scholar
• Steen E, Terry BM, Rivera EJ et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease – is this Type 3 diabetes? J. Alzheimers Dis.7, 63–80 (2005).
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J. Clin. Invest.116, 1793–1801 (2006).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature444, 860–867 (2006).
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Copeland PM et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch. Gen. Psychiatry62, 19–28 (2005).
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW, Fucetola R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry59, 337–345 (2002).
   PubMed Web of Science ®Google Scholar
• Muller N, Riedel M, Scheppach C et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry159, 1029–1034 (2002).
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol. Psychiatry57, 1594–1596 (2005).
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res.80, 19–32 (2005).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation109, 433–438 (2004).
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA288, 2709–2716 (2002).
   PubMed Web of Science ®Google Scholar
• Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry160, 284–289 (2003).
   PubMed Web of Science ®Google Scholar
• Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br. J. Psychiatry47, S76–S79 (2004).
   Google Scholar
• Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry65, 267–272 (2004).
   PubMed Web of Science ®Google Scholar
• Henderson DC, Nguyen DD, Copeland PM et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J. Clin. Psychiatry66, 1116–1121 (2005).
   PubMed Web of Science ®Google Scholar
• Bonora E, Kiechl S, Willeit J et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes47, 1643–1649 (1998).
   PubMed Web of Science ®Google Scholar
• Kitabchi AE, Temprosa M, Knowler WC et al. Role of insulin secretion and sensitivity in the evolution of Type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes54, 2404–2414 (2005).
   PubMed Web of Science ®Google Scholar
• Lillioja S, Mott DM, Spraul M et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N. Engl. J. Med.329, 1988–1992 (1993).
   PubMed Web of Science ®Google Scholar
• Semenkovich CF. Insulin resistance and atherosclerosis. J. Clin. Invest.116, 1813–1822 (2006).
   PubMed Web of Science ®Google Scholar
• Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of Type 2 diabetes development. Diabetes Care24, 89–94 (2001).
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J. Clin. Invest.115, 1111–1119 (2005).
   PubMed Web of Science ®Google Scholar
• Sjoholm A, Nystrom T. Inflammation and the etiology of Type 2 diabetes. Diabetes Metab. Res. Rev.22, 4–10 (2006).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science259, 87–91 (1993).
   PubMed Web of Science ®Google Scholar
• Dandona P, Aljada A, Chaudhuri A, Mohanty P. Endothelial dysfunction, inflammation and diabetes. Rev. Endocr. Metab. Disord.5, 189–197 (2004).
   PubMed Web of Science ®Google Scholar
• White MF. The insulin signalling system and the IRS proteins. Diabetologia40, S2–S17 (1997).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science271, 665–668 (1996).
   PubMed Web of Science ®Google Scholar
• Diamant M, Heine RJ. Thiazolidinediones in Type 2 diabetes mellitus: current clinical evidence. Drugs63, 1373–1405 (2003).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation106, 679–684 (2002).
   PubMed Web of Science ®Google Scholar
• Esposito K, Ciotola M, Carleo D et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care29, 1071–1076 (2006).
   PubMed Web of Science ®Google Scholar
• Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M. Association between -G308A tumor necrosis factor-α gene polymorphism and schizophrenia. Mol. Psychiatry6, 79–82 (2001).
   PubMed Web of Science ®Google Scholar
• Schwab SG, Mondabon S, Knapp M et al. Association of tumor necrosis factor-α gene–G308A polymorphism with schizophrenia. Schizophr. Res.65, 19–25 (2003).
   PubMedGoogle Scholar
• Tan EC, Chong SA, Tan CH, Teo YY, Peng K, Mahendran R. Tumor necrosis factor-α gene promoter polymorphisms in chronic schizophrenia. Biol. Psychiatry54, 1205–1211 (2003).
   PubMed Web of Science ®Google Scholar
• Riedel M, Kronig H, Schwarz MJ et al. No association between the G308A polymorphism of the tumor necrosis factor-α gene and schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci.252, 232–234 (2002).
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Hong CJ, Yu YW, Lin CH, Liu LL. No association of tumor necrosis factor-α gene polymorphisms with schizophrenia or response to clozapine. Schizophr. Res.65, 27–32 (2003).
   PubMed Web of Science ®Google Scholar
• Katila H, Hanninen K, Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol. Psychiatry4, 179–181 (1999).
   PubMed Web of Science ®Google Scholar
• Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology40, 171–176 (1999).
   PubMed Web of Science ®Google Scholar
• Owen BM, Eccleston D, Ferrier IN, Young AH. Raised levels of plasma interleukin-1β in major and postviral depression. Acta Psychiatr. Scand.103, 226–228 (2001).
   PubMedGoogle Scholar
• Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology22, 370–379 (2000).
   PubMed Web of Science ®Google Scholar